27777170|t|Rheumatoid arthritis, insulin resistance, and diabetes
27777170|a|Recent progress in the management of rheumatoid arthritis (RA) is turning attention toward comorbidities, such as diabetes. The objectives of this review are to clarify the links between RA and diabetes and to assess potential effects of disease-modifying antirheumatic drugs (DMARDs) on diabetes. The increased insulin resistance seen in RA is closely linked to the systemic inflammation induced by certain proinflammatory cytokines such as tumor necrosis factor α (TNFα) and interleukin-6. The prevalence of type 2 diabetes is increased in patients with RA. Furthermore, certain DMARDs including hydroxychloroquine, methotrexate, TNFα antagonist, and interleukin-1β antagonists seem to improve the markers of glucose metabolism. In contrast, glucocorticoids tend to adversely affect glycemic control, particularly when taken chronically. Consequently, a crucial yet insufficiently applied rule is that cardiovascular risk factors must be sought and treated routinely, particularly as the choice of the DMARD may affect glucose metabolism.
27777170	0	20	Rheumatoid arthritis	T038	UMLS:C0003873
27777170	22	40	insulin resistance	T038	UMLS:C0021655
27777170	46	54	diabetes	T038	UMLS:C0011847
27777170	78	88	management	T058	UMLS:C0376636
27777170	92	112	rheumatoid arthritis	T038	UMLS:C0003873
27777170	114	116	RA	T038	UMLS:C0003873
27777170	169	177	diabetes	T038	UMLS:C0011847
27777170	202	208	review	T170	UMLS:C0282443
27777170	242	244	RA	T038	UMLS:C0003873
27777170	249	257	diabetes	T038	UMLS:C0011847
27777170	293	330	disease-modifying antirheumatic drugs	T103	UMLS:C0242708
27777170	332	338	DMARDs	T103	UMLS:C0242708
27777170	343	351	diabetes	T038	UMLS:C0011847
27777170	367	385	insulin resistance	T038	UMLS:C0021655
27777170	394	396	RA	T038	UMLS:C0003873
27777170	463	488	proinflammatory cytokines	T103	UMLS:C0079189
27777170	497	520	tumor necrosis factor α	T103	UMLS:C1456820
27777170	522	526	TNFα	T103	UMLS:C1456820
27777170	532	545	interleukin-6	T103	UMLS:C0021760
27777170	565	580	type 2 diabetes	T038	UMLS:C0011860
27777170	611	613	RA	T038	UMLS:C0003873
27777170	636	642	DMARDs	T103	UMLS:C0242708
27777170	653	671	hydroxychloroquine	T103	UMLS:C0020336
27777170	673	685	methotrexate	T103	UMLS:C0025677
27777170	687	691	TNFα	T103	UMLS:C1456820
27777170	692	702	antagonist	T103	UMLS:C0243076
27777170	708	722	interleukin-1β	T103	UMLS:C0021753
27777170	723	734	antagonists	T103	UMLS:C0243076
27777170	743	750	improve	T033	UMLS:C0184511
27777170	755	762	markers	T103	UMLS:C1513159
27777170	766	784	glucose metabolism	T038	UMLS:C0596620
27777170	799	814	glucocorticoids	T103	UMLS:C0017710
27777170	840	856	glycemic control	T058	UMLS:C3267174
27777170	1059	1064	DMARD	T103	UMLS:C0242708
27777170	1076	1094	glucose metabolism	T038	UMLS:C0596620